Related Experiment Video

Updated: Jul 6, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Treating patients with non-STEMI: stent the culprit artery only or address all lesions?

Mehdi H Shishehbor1, Deepak L Bhatt

  • 1Department of Cardiovascular Medicine, Cleveland Clinic, Desk F-25, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

Current Treatment Options in Cardiovascular Medicine
|March 8, 2008
PubMed

Insights

For non-ST segment elevation myocardial infarction (non-STEMI), identifying the culprit lesion is challenging. We recommend stenting the culprit and other severe lesions, considering fractional flow reserve or intravascular ultrasound for unclear cases.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Acute Coronary Syndromes

Background:

  • Non-ST segment elevation myocardial infarction (non-STEMI) is a frequent acute coronary syndrome (ACS).
  • Current guidelines recommend invasive angiography and revascularization for the culprit lesion.
  • Identifying the specific culprit lesion in non-STEMI can be difficult, unlike in STEMI.

Purpose of the Study:

  • To evaluate the optimal revascularization strategy for patients with non-STEMI.
  • To address the challenges in identifying culprit lesions in non-STEMI.
  • To provide recommendations for managing multivessel disease in ACS.

Main Methods:

  • Review of current European and American College of Cardiology/American Heart Association guidelines for percutaneous coronary intervention (PCI) in ACS.
  • Analysis of treatment strategies for culprit-only versus complete revascularization.
  • Consideration of diagnostic tools like fractional flow reserve (FFR) and intravascular ultrasound (IVUS).

Main Results:

  • Guidelines offer individualized approaches for complete versus culprit-only revascularization.
  • The decision for PCI should balance success likelihood, risk, myocardial territory, and noninvasive testing.
  • Stenting culprit and other severe lesions, potentially in a staged manner, is recommended after careful evaluation.

Conclusions:

  • A tailored approach to revascularization in non-STEMI is crucial.
  • Fractional flow reserve or intravascular ultrasound can aid in assessing nonculprit lesion severity.
  • Careful consideration of individual lesion characteristics and patient risk is paramount for optimal outcomes.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...